Efficacy for LDL-C–lowering and safety of pemafibrate extended-release formulation in patients with statin-intolerant hypercholesterolemia: A phase 3 multicenter, randomized, double-blind, placebo-controlled, parallel-group trial

20261 citationsJournal Articlehybrid Open Access

Authors

Shizuya Yamashita · Tokyo Yamate Medical Center

Eiichi Araki · Kumamoto Health Science University

Hidenori Arai · National Center for Geriatrics and Gerontology

K. Yokote · Chiba University

Ryohei Tanigawa · Kowa (Japan)

Keisuke Kunitomi · Kowa (Japan)

Kaho Ikegami ·

Abstract

Pemafibrate effectively and safely reduces LDL-C in patients with statin-intolerant hypercholesterolemia and normal triglyceride levels, offering a potential new therapeutic option for this population.

Topics & Keywords

Lipoproteins and Cardiovascular Health Diabetes, Cardiovascular Risks, and Lipoproteins Lipid metabolism and disorders

UN Sustainable Development Goals

Good health and well-being

Publication Details

Published in: Journal of clinical lipidology

DOI: 10.1016/j.jacl.2026.01.008

Field-Weighted Citation Impact: 48.43